Instil Bio, Inc. (TIL)
NASDAQ: TIL · Real-Time Price · USD
10.92
-0.48 (-4.21%)
At close: Dec 5, 2025, 4:00 PM EST
11.34
+0.42 (3.85%)
After-hours: Dec 5, 2025, 7:47 PM EST
Instil Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
74.06M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
TIL News
- 23 days ago - Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Instil Bio Announces ImmuneOnco's Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC) - GlobeNewsWire
- 4 months ago - Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China - GlobeNewsWire
- 5 months ago - Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors - GlobeNewsWire
- 6 months ago - Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program - GlobeNewsWire
- 6 months ago - Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer - GlobeNewsWire
- 6 months ago - Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference - GlobeNewsWire